How much profit has Nektar Therapeutics made this year?
Nektar Therapeutics has made -156.14 M USD this year.
Nektar Therapeutics Net Income 2024
Nektar Therapeutics Net Income
-156.14 M USD
Ticker
NKTR
ISIN
US6402681083
WKN
165417
In 2024, Nektar Therapeutics's profit amounted to -156.14 M USD, a -43.44% increase from the -276.06 M USD profit recorded in the previous year.
The Nektar Therapeutics Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2030e | - |
| 2029e | - |
| 2028e | - |
| 2027e | - |
| 2026e | -115.66 |
| 2025e | -127.11 |
| 2024e | -156.14 |
| 2023 | -276.06 |
| 2022 | -368.2 |
| 2021 | -523.8 |
| 2020 | -444.4 |
| 2019 | -440.7 |
| 2018 | 681.3 |
| 2017 | -96.7 |
| 2016 | -153.5 |
| 2015 | -81.2 |
| 2014 | -53.9 |
| 2013 | -162 |
| 2012 | -171.9 |
| 2011 | -134 |
| 2010 | -37.9 |
| 2009 | -102.5 |
| 2008 | -34.3 |
| 2007 | -32.8 |
| 2006 | -154.8 |
| 2005 | -185.1 |
| 2004 | -101.9 |
Nektar Therapeutics Revenue, EBIT, Net Income US6402681083 · 165417
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Nektar Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nektar Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nektar Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Nektar Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Nektar Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Nektar Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nektar Therapeutics’s growth potential.
Nektar Therapeutics Revenue, EBIT and net profit per share
| Date | Nektar Therapeutics Revenue | Nektar Therapeutics EBIT | Nektar Therapeutics Net Income |
|---|---|---|---|
| 2030e | 192.68 M undefined | 19.89 M undefined | 0 undefined |
| 2029e | 61.71 M undefined | -43.04 M undefined | 0 undefined |
| 2028e | 197.55 M undefined | -46.97 M undefined | 0 undefined |
| 2027e | 113.83 M undefined | -154.69 M undefined | 0 undefined |
| 2026e | 67.17 M undefined | -179.72 M undefined | -115.66 M undefined |
| 2025e | 66.11 M undefined | -171.25 M undefined | -127.11 M undefined |
| 2024e | 78.9 M undefined | -157.63 M undefined | -156.14 M undefined |
| 2023 | 90.12 M undefined | -135.23 M undefined | -276.06 M undefined |
| 2022 | 92.1 M undefined | -240.3 M undefined | -368.2 M undefined |
| 2021 | 101.9 M undefined | -446.1 M undefined | -523.8 M undefined |
| 2020 | 152.9 M undefined | -379.9 M undefined | -444.4 M undefined |
| 2019 | 114.6 M undefined | -440 M undefined | -440.7 M undefined |
| 2018 | 1.19 B undefined | 687.9 M undefined | 681.3 M undefined |
| 2017 | 307.7 M undefined | -43.6 M undefined | -96.7 M undefined |
| 2016 | 165.4 M undefined | -112.9 M undefined | -153.5 M undefined |
| 2015 | 230.8 M undefined | -29.4 M undefined | -81.2 M undefined |
| 2014 | 200.7 M undefined | -16.5 M undefined | -53.9 M undefined |
| 2013 | 148.9 M undefined | -120.1 M undefined | -162 M undefined |
| 2012 | 81.2 M undefined | -139.5 M undefined | -171.9 M undefined |
| 2011 | 71.5 M undefined | -123.9 M undefined | -134 M undefined |
| 2010 | 159 M undefined | -15.7 M undefined | -37.9 M undefined |
| 2009 | 71.9 M undefined | -95.1 M undefined | -102.5 M undefined |
| 2008 | 90.2 M undefined | -150.8 M undefined | -34.3 M undefined |
| 2007 | 273 M undefined | -86.9 M undefined | -32.8 M undefined |
| 2006 | 217.7 M undefined | -132.1 M undefined | -154.8 M undefined |
| 2005 | 126.3 M undefined | -109.4 M undefined | -185.1 M undefined |
| 2004 | 114.3 M undefined | -73.9 M undefined | -101.9 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 114.3 M USD | -73.9 M USD | -101.9 M USD |
| 2005 | 126.3 M USD | -109.4 M USD | -185.1 M USD |
| 2006 | 217.7 M USD | -132.1 M USD | -154.8 M USD |
| 2007 | 273 M USD | -86.9 M USD | -32.8 M USD |
| 2008 | 90.2 M USD | -150.8 M USD | -34.3 M USD |
| 2009 | 71.9 M USD | -95.1 M USD | -102.5 M USD |
| 2010 | 159 M USD | -15.7 M USD | -37.9 M USD |
| 2011 | 71.5 M USD | -123.9 M USD | -134 M USD |
| 2012 | 81.2 M USD | -139.5 M USD | -171.9 M USD |
| 2013 | 148.9 M USD | -120.1 M USD | -162 M USD |
| 2014 | 200.7 M USD | -16.5 M USD | -53.9 M USD |
| 2015 | 230.8 M USD | -29.4 M USD | -81.2 M USD |
| 2016 | 165.4 M USD | -112.9 M USD | -153.5 M USD |
| 2017 | 307.7 M USD | -43.6 M USD | -96.7 M USD |
| 2018 | 1.19 B USD | 687.9 M USD | 681.3 M USD |
| 2019 | 114.6 M USD | -440 M USD | -440.7 M USD |
| 2020 | 152.9 M USD | -379.9 M USD | -444.4 M USD |
| 2021 | 101.9 M USD | -446.1 M USD | -523.8 M USD |
| 2022 | 92.1 M USD | -240.3 M USD | -368.2 M USD |
| 2023 | 90.12 M USD | -135.23 M USD | -276.06 M USD |
| 2024e | 78.9 M USD | -157.63 M USD | -156.14 M USD |
| 2025e | 66.11 M USD | -171.25 M USD | -127.11 M USD |
| 2026e | 67.17 M USD | -179.72 M USD | -115.66 M USD |
| 2027e | 113.83 M USD | -154.69 M USD | 0 USD |
| 2028e | 197.55 M USD | -46.97 M USD | 0 USD |
| 2029e | 61.71 M USD | -43.04 M USD | 0 USD |
| 2030e | 192.68 M USD | 19.89 M USD | 0 USD |
Nektar Therapeutics stock margins US6402681083 · 165417
The Nektar Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nektar Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nektar Therapeutics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Nektar Therapeutics's sales revenue. A higher gross margin percentage indicates that the Nektar Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Nektar Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Nektar Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nektar Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nektar Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nektar Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Nektar Therapeutics Margin History
| Nektar Therapeutics Gross margin | Nektar Therapeutics Profit margin | Nektar Therapeutics EBIT margin | Nektar Therapeutics Profit margin |
|---|---|---|---|
| 2030e | 62.53 % | 10.32 % | 0 % |
| 2029e | 62.53 % | -69.75 % | 0 % |
| 2028e | 62.53 % | -23.77 % | 0 % |
| 2027e | 62.53 % | -135.89 % | 0 % |
| 2026e | 62.53 % | -267.55 % | -172.19 % |
| 2025e | 62.53 % | -259.04 % | -192.28 % |
| 2024e | 62.53 % | -199.78 % | -197.9 % |
| 2023 | 62.53 % | -150.05 % | -306.31 % |
| 2022 | 76.44 % | -260.91 % | -399.78 % |
| 2021 | 75.56 % | -437.78 % | -514.03 % |
| 2020 | 87.25 % | -248.46 % | -290.65 % |
| 2019 | 81.33 % | -383.94 % | -384.55 % |
| 2018 | 97.96 % | 57.65 % | 57.09 % |
| 2017 | 90.09 % | -14.17 % | -31.43 % |
| 2016 | 81.74 % | -68.26 % | -92.81 % |
| 2015 | 85.23 % | -12.74 % | -35.18 % |
| 2014 | 85.8 % | -8.22 % | -26.86 % |
| 2013 | 74.14 % | -80.66 % | -108.8 % |
| 2012 | 62.56 % | -171.8 % | -211.7 % |
| 2011 | 69.37 % | -173.29 % | -187.41 % |
| 2010 | 83.9 % | -9.87 % | -23.84 % |
| 2009 | 57.02 % | -132.27 % | -142.56 % |
| 2008 | 61.09 % | -167.18 % | -38.03 % |
| 2007 | 45.97 % | -31.83 % | -12.01 % |
| 2006 | 45.75 % | -60.68 % | -71.11 % |
| 2005 | 71.5 % | -86.62 % | -146.56 % |
| 2004 | 82.68 % | -64.65 % | -89.15 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 82.68 % | -64.65 % | -89.15 % |
| 2005 | 71.5 % | -86.62 % | -146.56 % |
| 2006 | 45.75 % | -60.68 % | -71.11 % |
| 2007 | 45.97 % | -31.83 % | -12.01 % |
| 2008 | 61.09 % | -167.18 % | -38.03 % |
| 2009 | 57.02 % | -132.27 % | -142.56 % |
| 2010 | 83.9 % | -9.87 % | -23.84 % |
| 2011 | 69.37 % | -173.29 % | -187.41 % |
| 2012 | 62.56 % | -171.8 % | -211.7 % |
| 2013 | 74.14 % | -80.66 % | -108.8 % |
| 2014 | 85.8 % | -8.22 % | -26.86 % |
| 2015 | 85.23 % | -12.74 % | -35.18 % |
| 2016 | 81.74 % | -68.26 % | -92.81 % |
| 2017 | 90.09 % | -14.17 % | -31.43 % |
| 2018 | 97.96 % | 57.65 % | 57.09 % |
| 2019 | 81.33 % | -383.94 % | -384.55 % |
| 2020 | 87.25 % | -248.46 % | -290.65 % |
| 2021 | 75.56 % | -437.78 % | -514.03 % |
| 2022 | 76.44 % | -260.91 % | -399.78 % |
| 2023 | 62.53 % | -150.05 % | -306.31 % |
| 2024e | 62.53 % | -199.78 % | -197.9 % |
| 2025e | 62.53 % | -259.04 % | -192.28 % |
| 2026e | 62.53 % | -267.55 % | -172.19 % |
| 2027e | 62.53 % | -135.89 % | 0 % |
| 2028e | 62.53 % | -23.77 % | 0 % |
| 2029e | 62.53 % | -69.75 % | 0 % |
| 2030e | 62.53 % | 10.32 % | 0 % |
Nektar Therapeutics Aktienanalyse
What does Nektar Therapeutics do?
"Answer: Nektar Therapeutics is an American biopharmaceutical company based in San Francisco, specializing in the discovery and development of drugs for the treatment of cancer, autoimmune, and chronic metabolic diseases. The company was founded in 1990 by CEO Howard Robin and his team, initially focused on researching new technologies for drug development and later shifted to developing drugs for cancer therapy. Nektar Therapeutics has a unique business model that involves partnering with major pharmaceutical companies and other partners to develop a wide range of products, which are then licensed to these partners for commercialization and distribution. The company operates in several sectors, including oncology, pain management, autoimmune diseases, and metabolic diseases. Its important products include Movantik for opioid-induced constipation and ONZEALD for pancreatic cancer treatment. Nektar Therapeutics has made significant progress in developing immunoncology drugs, with potential projects such as NKTR-214 for advanced skin cancers. With its leading position in innovative drug development and strategic partnerships, the company has the potential to become a major player in cancer therapy." Nektar Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Nektar Therapeutics's Profit Margins
The profit margins of Nektar Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Nektar Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Nektar Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Nektar Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Nektar Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Nektar Therapeutics stock
How has the profit developed compared to last year?
The profit has increased by -43.44% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Nektar Therapeutics publish its earnings?
Nektar Therapeutics publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Nektar Therapeutics?
The profits of Nektar Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Nektar Therapeutics?
You can learn more about the earnings of Nektar Therapeutics by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Nektar Therapeutics pay?
Over the past 12 months, Nektar Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nektar Therapeutics is expected to pay a dividend of 0 USD.
What is the dividend yield of Nektar Therapeutics?
The current dividend yield of Nektar Therapeutics is .
When does Nektar Therapeutics pay dividends?
Nektar Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Nektar Therapeutics?
Nektar Therapeutics paid dividends every year for the past 0 years.
What is the dividend of Nektar Therapeutics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Nektar Therapeutics located?
Nektar Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Nektar Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Nektar Therapeutics from 9/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.
When did Nektar Therapeutics pay the last dividend?
The last dividend was paid out on 9/22/2024.
What was the dividend of Nektar Therapeutics in the year 2023?
In the year 2023, Nektar Therapeutics distributed 0 USD as dividends.
In which currency does Nektar Therapeutics pay out the dividend?
The dividends of Nektar Therapeutics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Nektar Therapeutics stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Nektar Therapeutics
Our stock analysis for Nektar Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nektar Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Nektar Therapeutics Revenue
- Nektar Therapeutics Net Income
- Nektar Therapeutics P/E
- Nektar Therapeutics P/S
- Nektar Therapeutics EBIT
- Nektar Therapeutics Dividend
- Nektar Therapeutics Stocks
- Nektar Therapeutics Market capitalization
- Nektar Therapeutics Debt
- Nektar Therapeutics Liabilities
- Nektar Therapeutics Equity
- Nektar Therapeutics AAQS
- Nektar Therapeutics Employees
- Nektar Therapeutics ROE
- Nektar Therapeutics ROA
- Nektar Therapeutics ROCE
